Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Single-Dose LY3461767 in HFrEF
NCT04840914Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2021
- Primary completion
- May 2024
- Modality
- Small Molecules, Blood Coagulation Factors
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) comparing LY3461767 with Placebo (2 arms). Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) Considered by the Investigator to be Related to Study Drug Administration at Day 90. Started Jun 2021; status: completed.
02
Drugs
LY3461767
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT04840914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04840914.